| Screening and pre-randomization assessment | Double-blind phase | Follow-up | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Visit number | S1 | V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | V9 | V10 | V11 |
Week |  | −1 | −1 | 0 | 1 | 2 | 4 | 5 | 5 | 6 | 7 | 10 |
Day |  | −7 | −1 | 0 | 7 | 14 | 28 | 35 | 36 | 42 | 49 | 70 |
Informed consent | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Demographics/Hollingshead | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Vital signs | X | X | X | X | X | X | X | X | X | X | X | X |
Weight | X | Â | Â | X | Â | Â | X | Â | Â | X | X | X |
Physical examination | X | Â | Â | Â | Â | Â | Â | Â | Â | X | Â | Â |
12-lead ECG | X | Â | X | Â | Â | Â | X | Â | Â | X | Â | Â |
SCID-IV | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Dispense study drug and diary | Â | Â | Â | X | X | X | X | Â | Â | Â | Â | Â |
Screening laboratory tests | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Fecal occult test | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Safety laboratory testing | Â | Â | X | X | X | X | X | Â | Â | X | Â | Â |
Pregnancy testing | X | Â | X | Â | Â | Â | Â | Â | Â | X | Â | X |
Pharmacokinetics | Â | Â | Â | Â | X | X | X | Â | Â | X | Â | X |
Psychiatric measures | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
CAPS/MADRS/CSSRS/CGI | X | Â | Â | X | X | X | X | Â | Â | X | X | X |
PSS-SR/QIDS-SR | X | Â | Â | X | X | X | X | Â | Â | X | X | X |
CTQ and PDS screen | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
PSQI/BPI | X | Â | Â | X | Â | Â | X | Â | Â | X | Â | X |
SDS | Â | Â | Â | X | Â | Â | Â | Â | Â | X | Â | Â |
LES | Â | Â | Â | X | Â | Â | Â | Â | Â | X | Â | Â |
Safety measures | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Adverse events/Concomitant medications | X | X | X | X | X | X | X | X | X | X | X | X |
PRISE | X | Â | Â | X | X | X | X | Â | Â | X | Â | Â |
FIBSER | Â | Â | Â | Â | X | X | X | Â | Â | X | X | X |
Exploratory aims | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Neuroendocrine measures | Â | Â | X | X | Â | Â | Â | X | X | Â | Â | Â |
Startle testing | Â | X | Â | Â | Â | Â | Â | X | Â | Â | Â | Â |
Neuropsychological testing | Â | X | Â | Â | Â | Â | Â | X | Â | Â | Â | Â |
Genotype | Â | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â |
mRNA | Â | Â | X | Â | Â | Â | Â | X | Â | Â | Â | Â |